Evidence map›Paper›PMID 32466790›Full record

ArticleCardiovascular ultrasound2020

Incremental prognostic value of echocardiography of left ventricular remodeling and diastolic function in STICH trial.

Kyung-Hee Kim, Lilin She, Kerry L Lee, Rafal Dabrowski, Paul A Grayburn, Miroslaw Rajda, David L Prior, Patrice Desvigne-Nickens, William A Zoghbi, Michele Senni and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cardiovascular ultrasound, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 6 countries.

Kyung-Hee KimDivision of Cardiovascular Diseases, Sejong General Hospital, Bucheon, South Korea.
Lilin SheDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Kerry L LeeDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Rafal DabrowskiNational Institute of Cardiology, Warsaw, Poland.
Paul A GrayburnBaylor University Medical Center, Dallas, TX, USA.
Miroslaw RajdaCapital Health Queen Elizabeth II Health Sciences Centre, Halifax, Canada.
David L PriorSt. Vincent's Hospital, Melbourne, Australia.
Patrice Desvigne-Nickens, Washington, DC, USA.
William A ZoghbiCardiovascular Imaging Institute, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Michele SenniHospital, Papa Giovanni XXIII, Bergamo, Italy.
Guglielmo StefanelliHesperia Hospital, Modena, Italy.
Cesare BeghiOspedale di Circolo, University of Insubria, Varese, Italy.
Thao HuynhMontreal General Hospital, McGill Health University Center, Montreal, Canada.
Eric J VelazquezYale School of Medicine, New Haven, CT, USA.
Jae K OhDivision of Cardiovascular Diseases, Echocardiography Core Laboratory, Mayo Clinic, Gonda 6 South, 200 First St SW, Rochester, MN, USA.
Grace LinDivision of Cardiovascular Diseases, Echocardiography Core Laboratory, Mayo Clinic, Gonda 6 South, 200 First St SW, Rochester, MN, USA. lin.grace@mayo.edu.
Clinical Research Institute · USMayo Clinic · USBaylor University Medical Center · USCore Laboratories (United States) · USHesperia Hospital · ITHouston Methodist · USInstitute of Cardiology · PLMontreal General Hospital · CAOspedale Papa Giovanni XXIII · ITQueen Elizabeth II Health Sciences Centre · CASt Vincent's Hospital · AUUniversity of Insubria · ITYale University · US

Funding

Foundation for the National Institutes of Health U01HL69015, U01HL69013, and U01HL69010
6 · The paper itself

Abstract

aimsWe sought to determine which echocardiographic markers of left ventricular (LV) remodeling and diastolic dysfunction can contribute as incremental and independent prognostic information in addition to current clinical risk markers of ischemic LV systolic dysfunction in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. METHODS AND

resultsThe cohort consisted of 1511 of 2136 patients in STICH for whom baseline transmitral Doppler (E/A ratio) could be measured by an echocardiographic core laboratory blinded to treatment and outcomes, and prognostic value of echocardiographic variables was determined by a Cox regression model. E/A ratio was the most significant predictor of mortality amongst diastolic variables with lowest mortality for E/A closest 0.8, although mortality was consistently low for E/A 0.6 to 1.0. Mortality increased for E/A < 0.6 and > 1.0 up to approximately 2.3, beyond which there was no further increase in risk. Larger LV end-systolic volume index (LVESVI) and E/A < 0.6 and > 1.0 had incremental negative effects on mortality when added to a clinical multivariable model, where creatinine, LVESVI, age, and E/A ratio accounted for 74% of the prognostic information for predicting risk. LVESVI and E/A ratio were stronger predictors of prognosis than New York Heart Association functional class, anemia, diabetes, history of atrial fibrillation, and stroke.

conclusionsEchocardiographic markers of advanced LV remodeling and diastolic dysfunction added incremental prognostic value to current clinical risk markers. LVESVI and E/A ratio outperformed other markers and should be considered as standard in assessing risks in ischemic heart failure. E/A closest to 0.8 was the most optimal filling pattern.

Indexed as

EchocardiographyAgedCohort StudiesFemaleHeart FailureHumansMaleMiddle AgedMyocardial IschemiaPredictive Value of TestsPrognosisVentricular Dysfunction, LeftVentricular RemodelingDiastolic dysfunction.Heart failureIschemic cardiomyopathy

Identifiers

PMID32466790
PMCPMC7257201
OpenAlexW3030455854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.